Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 53 Neoplasm Metastasis 16 Carcinoma, Non-Small-Cell Lung 10 Neoplasms 7 Brain Neoplasms 5 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasms by Site 3 Melanoma 3 Glioma 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Breast Diseases 3 Sarcoma, Ewing 2 Recurrence 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Lymphoma 2 Glioblastoma 2 Advanced Cancer 2 Uterine Cervical Neoplasms 1 Urogenital Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Spinal Cord Neoplasms 1 Solid Tumor, Adult 1 Sarcoma 1 Rhabdomyosarcoma 1

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × HR+/HER2- Breast Cancer × abemaciclib × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡